SCHEMBL3569468

SCHEMBL3569468

NC(=O)N(c1ccc(Cl)cc1)C(C(=O)O)c1ccccc1OC(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
MAP2 P11137 1/20 0.38
ANO1 Q5XXA6 1/20 0.37
PNLIP P16233 1/20 0.37
MGLL Q99685 2/20 0.35
SCN10A Q9Y5Y9 1/20 0.34
KCNK3 O14649 1/20 0.34
KCNK9 Q9NPC2 1/20 0.34
MDM2 Q00987 4/20 0.34
MDM4 O15151 1/20 0.34
AVPR2 P30518 1/20 0.34
GPR27 Q9NS67 1/20 0.34
IDH1 O75874 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.33
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
RXRG P48443 1/20 0.33
SLC1A5 Q15758 1/20 0.32
BCL2A1 Q16548 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3566188 0.85 ATM (0.45)
SCHEMBL3573000 0.83 PPARA (0.44) PNLIPSLC1A5PPARGPPARA
SCHEMBL3569300 0.80 CNR2 (0.41) MDM2MDM4PPARGPPARA
SCHEMBL3563022 0.80 MDM2 (0.41) MDM2MDM4PPARGPPARA
SCHEMBL3568224 0.79 KIF11 (0.33) MDM2MDM4PPARGPPARA
SCHEMBL3563412 0.78 PPARA (0.38) MDM2MDM4PPARGPPARA
SCHEMBL3564244 0.78 CES2 (0.36) MDM2MDM4PPARGPPARA
SCHEMBL3557436 0.78 PPARG (0.38) MDM2TRPM8PPARGPPARA
SCHEMBL3561429 0.78 PCTP (0.36) ANO1PNLIPKCNK3KCNK9AVPR2
SCHEMBL3566287 0.76 F10 (0.38) ANO1PNLIPIDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 CYP11B1 672/4885CYP11B2 1058/4885MAP2 4206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.